4-(5-methanesulfonylthiophene-2-yl)benzaldehyde | 1313758-53-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(5-methanesulfonylthiophene-2-yl)benzaldehyde
• 英文别名: 4-(5-Methylsulfonylthiophen-2-yl)benzaldehyde
• CAS: 1313758-53-0
• 化学式: C₁₂H₁₀O₃S₂
• 分子量: 266.342
• InChiKey: APARIDJHVDWDTM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  87.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-甲基磺酰噻吩 、 对溴苯甲醛 在 potassium acetate 、 palladium diacetate 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 16.0h， 以74%的产率得到4-(5-methanesulfonylthiophene-2-yl)benzaldehyde
  参考文献：
  名称：

  Palladium-Catalyzed Direct Arylation of Thiophenes Bearing SO₂R Substituents

  摘要：

  The palladium-catalyzed direct arylation of SO2R-substituted thiophene derivatives was found to proceed regioselectively at CS and in high yields using a variety of aryl bromides and as low as 0.5-0.1 mol % of phosphine-free Pd(OAc)(2) as the catalyst. For these reactions, sulfonyls, sulfonamides, or even a sulfonic ester as the thiophene substituents were successfully employed.

  DOI：

  10.1021/jo200918n

文献信息

• HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES
  申请人：Finley Don Richard

  公开号：US20090048225A1

  公开（公告）日：2009-02-19

  The present invention provides a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof, having histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another, embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.

  本发明提供一种新型化合物(I)或其药学上可接受的盐，具有组胺H3受体拮抗剂或反向激动剂的活性，以及制备这种化合物的方法。在另一种实施方式中，本发明揭示了包含化合物(I)的药物组合物，以及使用它们治疗肥胖症、认知缺陷、嗜睡症和其他组胺H3受体相关疾病的方法。
• Histamine H3 Receptor Agents, Preparation and Therapeutic Uses
  申请人：FINLEY Don Richard

  公开号：US20100029608A1

  公开（公告）日：2010-02-04

  The present invention provides a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof, having histamine-113 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another, embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.

  本发明提供了一种新的化合物（I）或其药学上可接受的盐，具有组胺113受体拮抗剂或反向激动剂活性，以及制备这种化合物的方法。在另一种实施方式中，本发明揭示了包含化合物（I）的制药组合物，以及使用它们治疗肥胖症、认知缺陷、嗜睡症和其他组胺H3受体相关疾病的方法。
• US7705025B2
  申请人：——

  公开号：US7705025B2

  公开（公告）日：2010-04-27
• Palladium-Catalyzed Direct Arylation of Thiophenes Bearing SO₂R Substituents
  作者：Charles Beromeo Bheeter、Jitendra K. Bera、Henri Doucet

  DOI：10.1021/jo200918n

  日期：2011.8.5

  The palladium-catalyzed direct arylation of SO2R-substituted thiophene derivatives was found to proceed regioselectively at CS and in high yields using a variety of aryl bromides and as low as 0.5-0.1 mol % of phosphine-free Pd(OAc)(2) as the catalyst. For these reactions, sulfonyls, sulfonamides, or even a sulfonic ester as the thiophene substituents were successfully employed.